CNBX OTC
CNBX Pharmaceuticals Inc.
1W: +0.0%
1M: -0.0%
3M: -44.4%
YTD: -75.0%
1Y: -71.4%
3Y: -99.5%
5Y: -100.0%
$0.00
-0.00 (-0.00%)
Weekly Expected Move ±4952.9%
$-0
$-0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
-100.0% ▼
Gross Profit
$0
-100.0% ▼
Operating Income
-$272K
+53.4% ▲
Net Income
-$314K
+54.8% ▲
EPS (Diluted)
$-0.00
+84.8% ▲
EBITDA
-$274K
+54.6% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $30K | $410K | $130K | $0 |
| YoY Growth | -100.0% | +0.0% | +1269.1% | -68.3% | -100.0% |
| Cost of Revenue | $221K | $199K | $0 | $0 | $0 |
| Gross Profit | -$221K | -$169K | $410K | $130K | $0 |
| Gross Margin | — | -564.1% | 100.0% | 100.0% | — |
| R&D Expenses | $2M | $1M | $432K | $195K | $0 |
| SG&A Expenses | $829K | $2M | $910K | $518K | $272K |
| Operating Expenses | $3M | $3M | $1M | $713K | $272K |
| Operating Income | -$3M | -$3M | -$931K | -$583K | -$272K |
| Operating Margin | — | -9860.5% | -227.0% | -448.2% | — |
| Interest Expense | $2K | $1K | $1K | $20K | $40K |
| Income Before Tax | -$3M | -$4M | -$4M | -$695K | -$314K |
| Tax Expense | $0 | $46K | $0 | $0 | $0 |
| Net Income | -$3M | -$4M | -$4M | -$695K | -$314K |
| Net Margin | — | -12427.4% | -904.5% | -534.3% | — |
| EPS (Diluted) | $-2.16 | $-3.59 | $-0.42 | $-0.02 | $-0.00 |
| EBITDA | -$3M | -$4M | -$4M | -$603K | -$274K |
| Shares Outstanding | 1M | 1M | 9M | 30M | 91M |